dc.contributor.author | Malmin, Agni | |
dc.contributor.author | Thomseth, Vilde Marie | |
dc.contributor.author | Førland, Per Tore | |
dc.contributor.author | Khan, Ayyad Ahmad Zartasht | |
dc.contributor.author | Hetland, Hanne Brit | |
dc.contributor.author | Chen, Xiangjun | |
dc.contributor.author | Haugen, Inga Britt Kjellevold | |
dc.contributor.author | Utheim, Tor Paaske | |
dc.contributor.author | Forsaa, Vegard Asgeir | |
dc.date.accessioned | 2023-08-23T09:07:27Z | |
dc.date.available | 2023-08-23T09:07:27Z | |
dc.date.created | 2023-04-20T15:07:49Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Malmin, A., Thomseth, V.M., Førland, P.T., Khan, A.Z. Hetland, H.B., Chen, X., Haugen, I-B.K., Utheim, T.P., Forsaa, V.A.(2023) Associations between Serial Intravitreal Injections and Dry Eye. Ophthalmology (Rochester, Minn.), 130 (5), 509-515. | en_US |
dc.identifier.issn | 0161-6420 | |
dc.identifier.uri | https://hdl.handle.net/11250/3085382 | |
dc.description.abstract | Purpose
To investigate the effects of serial intravitreal injections (IVIs) on the ocular surface and meibomian glands (MGs) in patients treated with anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD).
Design
Retrospective, controlled, observational study.
Participants
Patients with nAMD receiving unilateral IVIs with anti-VEGF agents. The fellow eye was used as control.
Methods
Tear film and ocular surface examinations were performed on a single occasion at a minimum of 4 weeks after IVI. A pre-IVI asepsis protocol with povidone-iodine (PVP-I) was applied.
Main Outcome Measures
Upper and lower MG loss, tear meniscus height (TMH), bulbar redness (BR) score, noninvasive tear break-up time (NIBUT), tear film osmolarity (TOsm), Schirmer test, corneal staining, fluorescein tear film break-up time (TBUT), meibomian gland expressibility (ME), and meibum quality.
Results
Ninety patients with a mean age of 77.5 years (standard deviation [SD], 8.4; range 54–95) were included. The median number of IVIs in treated eyes was 19.5 (range, 2–132). Mean MG loss in the upper eyelid was 19.1% (SD, 11.3) in treated eyes and 25.5% (SD, 14.6) in untreated fellow eyes (P = 0.001). For the lower eyelid, median MG loss was 17.4% (interquartile range [IQR], 9.4–29.9) in treated eyes and 24.5% (IQR, 14.2–35.2) in fellow eyes (P < 0.001). Mean BR was 1.32 (SD, 0.46) in treated eyes versus 1.44 (SD, 0.45) in fellow eyes (P = 0.017). Median TMH was 0.36 mm (IQR, 0.28–0.52) in treated eyes and 0.32 mm (IQR, 0.24–0.49) in fellow eyes (P = 0.02). There were no differences between treated and fellow eyes regarding NIBUT, TOsm, Schirmer test, corneal staining, fluorescein TBUT, ME, or meibum quality.
Conclusions
Repeated IVIs with anti-VEGF with preoperative PVP-I application was associated with reduced MG loss, increased tear volume, and reduced signs of inflammation compared with fellow nontreated eyes in patients with nAMD. This regimen may thus have a beneficial effect on the ocular surface. | en_US |
dc.language.iso | eng | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | oftalmologi | en_US |
dc.title | Associations between Serial Intravitreal Injections and Dry Eye | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2023 by the American Academy of Ophthalmology | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Oftalmologi: 754 | en_US |
dc.source.pagenumber | 509-515 | en_US |
dc.source.volume | 130 | en_US |
dc.source.journal | Ophthalmology | en_US |
dc.source.issue | 5 | en_US |
dc.identifier.doi | 10.1016/j.ophtha.2023.01.009 | |
dc.identifier.cristin | 2142232 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |